Assets változás Dátum
AbbVie USD 136.22B 854M 2023-09
Acadia Pharmaceuticals USD 748.96M 116.42M 2023-12
Acorda Therapeutics USD 364.7M 10.21M 2023-06
Agios Pharmaceuticals USD 937.12M 70.14M 2023-12
ALKERMES USD 2.28B 92.05M 2023-09
Alnylam Pharmaceuticals USD 3.83B 9.19M 2023-12
Amgen USD 97.15B 6.62B 2023-12
Biogen USD 26.84B 1.35B 2023-12
BioMarin Pharmaceutical USD 6.84B 83.44M 2023-12
Cytokinetics USD 824.32M 83.7M 2023-12
Dynavax Technologies USD 997.1M 24.16M 2023-12
Enanta Pharmaceuticals USD 462.28M 32.89M 2023-09
Exelixis USD 2.98B 165.56M 2023-09
Gilead Sciences USD 62.13B 248M 2023-12
Halozyme Therapeutics USD 1.73B 159.39M 2023-12
Incyte USD 6.78B 393.87M 2023-12
Intra Cellular Therapies USD 728.3M 10.63M 2023-12
Ionis Pharmaceuticals USD 2.99B 56.1M 2023-12
Nektar Therapeutics USD 442.24M 52.04M 2023-09
Neurocrine Biosciences USD 2.85B 235.1M 2023-09
Pfizer USD 215.02B 5.15B 2023-09
Regeneron Pharmaceuticals USD 33.08B 916.9M 2023-12
Repligen USD 952.88M 1.56B 2023-12
Rigel Pharmaceuticals USD 115.32M 1.77M 2023-09
Sarepta Therapeutics USD 3.11B 16.18M 2023-09
Teva Pharmaceutical Industries USD 42.09B 1.01B 2023-09
Ultragenyx Pharmaceutical USD 1.49B 252.87M 2023-12
Vertex Pharmaceuticals USD 21.73B 1.38B 2023-09
Xoma USD 124.09M 1.57M 2023-09



Neurocrine Biosciences Eszközök - Az oldal aktuális és múlbeli adatokat, elorejelzéseket, statisztikákat, grafikonokat és a gazdasági naptár adatait tartalmazza - Mar 2024.